Atara Biotherapeutics Profit Margin

The latest profit margin for ATRA is -48.09% as of March 2026. That compares with -15.4% in the prior-year period — down 212.3% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Atara Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ATRA's profit margin moved from -15.4% to -48.09% — a 212.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Atara Biotherapeutics's valuation or profitability profile.

Against Healthcare companies, ATRA currently prints -48.09% for profit margin, while the sector average sits near 14.34%. That is roughly 435.2% below the sector mean. Large gaps often invite a closer look at Atara Biotherapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Atara Biotherapeutics converts resources into returns. At -48.09%, ATRA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -15.4% in the prior-year period — down 212.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ATRA's profit margin (-48.09%), review year-over-year change from -15.4%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.